Literature DB >> 25169975

HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review.

Nikoline S Karlsen1, Mona A Karlsen2, Claus K Høgdall3, Estrid V S Høgdall4.   

Abstract

Human epididymis protein 4 (HE4) has received major attention as a potential tumor marker in epithelial ovarian cancer; however, evidence of significant overexpression of HE4 in several other human cancers is expanding. To assess the possible limitations or benefits of HE4 in a clinical setting, this review aims to systematically outline published results of HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors. Our findings suggest scientific basis for a potential diagnostic ability of HE4 in gynecologic cancer and lung cancer, and further research is needed regarding other cancers. Yet, it is important to recognize that other malignancies can cause increased HE4 levels. Furthermore, attention should be paid to the influence of age and renal function on HE4 serum levels in future studies as well as in the clinic for proper interpretation of serum HE4 test results. Cancer Epidemiol Biomarkers Prev; 23(11); 2285-95. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25169975     DOI: 10.1158/1055-9965.EPI-14-0447

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  23 in total

Review 1.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

2.  Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios
Journal:  Clin Transl Oncol       Date:  2017-08-16       Impact factor: 3.405

3.  Falsely elevated human epididymis protein 4 results and Risk of Ovarian Malignancy Algorithm in polymorbid women after solid organ transplantation: A pilot and case-control study.

Authors:  Janka Franeková; Josef Cindr; Petra Lavríková; Jitka Komrsková; Peter Sečník; Věra Lánská; Antonín Jabor
Journal:  J Clin Lab Anal       Date:  2018-03-24       Impact factor: 2.352

4.  Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling.

Authors:  Jinli Wang; Hongyang Zhao; Fenfen Xu; Piaopiao Zhang; Yuan Zheng; Nan Jia
Journal:  Genes Genomics       Date:  2019-06-04       Impact factor: 1.839

5.  Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer.

Authors:  Wu Meng; Wang Ying; Zheng Qichao; Li Ping; Tang Jie
Journal:  Saudi Med J       Date:  2017-06       Impact factor: 1.484

6.  A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Authors:  Mona Aarenstrup Karlsen; Carsten Fagö-Olsen; Estrid Høgdall; Tine Henrichsen Schnack; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Magnus Christian Lydolph; Svend Aage Engelholm; Claus Høgdall
Journal:  Tumour Biol       Date:  2016-07-20

7.  Value of serum marker HE4 in pulmonary carcinoma diagnosis.

Authors:  Qin-Fang Tang; Zhong-Wei Zhou; Hong-Bing Ji; Wu-Hua Pan; Ming-Zhong Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).

Authors:  Daniel W Cramer; Allison F Vitonis; Naoko Sasamoto; Hidemi Yamamoto; Raina N Fichorova
Journal:  Gynecol Oncol       Date:  2021-01-24       Impact factor: 5.482

9.  Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.

Authors:  Fenfen Zhang; Yao Liu; Quan Quan; Yu Meng; Xiaoling Mu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

10.  HE4, A New Potential Tumor Marker for Early Diagnosis and Predicting of Breast Cancer Progression.

Authors:  Nazanin Mirmohseni Namini; Alireza Abdollahi; Monireh Movahedi; Amirnader Emami Razavi; Reza Saghiri
Journal:  Iran J Pathol       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.